CARsgen Enters into Partnership Agreement with Shanghai Cancer Institute to Develop Novel CAR-T Technology
Sep 29, 2015
SHANGHAI, September 29, 2015 /PRNewswire/ -- CARsgen Therapeutics, a private and venture backed company focused on the development of CAR-T-based autologous immunotherapy to treat solid tumors, today provided a business and clinical update on its immunotherapy programs.